Delivery of the TRAIL plasmid using these targeted polymers led to death in 30–40% cancer cells, which, although modest is promising since TRAIL can be synergized with other therapeutics resulting in significant loss of viability in cancer cells. The gene discussed is TNFSF10; the disease is cancer.